Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT for Cutaneous SCC in Situ
NCT03025724Unknown
- Sponsor
- Rhode Island Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of 5-aminolevulinic acid in squamous cell carcinoma (SCC) (2 arms), sponsored by Rhode Island Hospital. Primary endpoint: Incidence of SCCis present after exposure to the experimental procedures at 6 months. Status: unknown.
02
Drugs
5-aminolevulinic acid
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT03025724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025724.